{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/657b178ababc4c0017c46b78/6a85bd5d6701ba1ebb5db46e?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability ","description":"<p>Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.</p><p><br></p><p>In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.</p><p><br></p><p>Guest Speakers</p><p>Steve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.</p><p>Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.</p><p>Bill Dubay -- VP, Global Research and Development, SK Pharmteco.</p><p><br></p><p>Moderator:</p><p>Kevin Davies, PhD, Editorial Director, GEN</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}